2020 Partners
Sanofi Digital Medicine, under the Chief Medical Office, improves patient outcomes through the development of innovative technology-driven solutions that when combined with drugs, improve treatment efficacy, safety, adherence and overall experience.
Be part of the 300+ person audience of senior executives who are driving forward the development of Digital Therapeutics
Learn from the industry-defining speaker faculty, comprised of the pioneers of the industry and the most exciting new-comers
Launching in 2018, DTx West has been the home for the digital therapeutics industry, acting as the platform for the field to connect, share and grow together.
The DTx Series is my go-to place for staying up-to-date and meeting all of the key players in this promising new digital health category.
I am excited to attend DTx for the fourth time. Whether as a presenter or part of the audience, I learn so much from other Digital Therapeutic executives and attendees about topics ranging from clinical trials to commercialization and everything in between!
I have been to the two editions of DTx West and I’m looking forward to attending DTx East this year. The conference brings together key leaders from across the digital health space to discuss new ideas and ongoing trends that are useful takeaways to bring back to my team.
“Thanks for catalyzing the industry forward in this emerging field. Looking forward to the next one”
“The DTx Series is a fantastic set of meetings. The quality of the investors, entrepreneurs and companies never fails to impress me, and I always leave having learned a lot”
“DTx is an inclusive event, where the participants truly believe that the rising tide will raise all boats”
“DTx is a great event! there is a great mix of digital innovators and large companies which deliver high-quality content. I learn a lot and it’s great to see this community come together and have authentic interactions”
2020 Speakers
Summit Workshops
- The Business of Digital Therapeutics
- Separating the Digital from the Traditional
Debra Reisenthel, President & CEO, Palo Alto Health Sciences
Everett Crosland, VP of Market Access, Reimbursement & Government Affairs, AppliedVR
Jonas Duss, US Chief Executive Officer, Kaia Health
Antoun Nabhan, VP, Corporate Development, Pear Therapeutics
- A brief overview of the various business models adopted by digital therapeutic companies
- An insight into the various routes to market
- Can DTx companies exist with both FDA and Non-FDA regulated therapeutics or do you have to “pick a side”
Splitting into smaller groups, you will discuss the intricacies of the business of digital therapeutics and hear views on how best to successfully run a business in the DTx industry.
- What are the current business models being used within the industry and which are demonstrating the most success?
- How do some business models favor certain types of digital therapeutic over others?
- Can a digital therapeutic company successfully develop and market both FDA & non-FDA regulated digital therapeutics?
- What are the route to market opportunities available to the DTx industry?
Representative(s) from each group share the main points from their discussion to the whole group. Additional questions from moderators and other group members will be raised during this collaborative discussion.
Summary thoughts will then be shared by the moderator(s) and all participants will leave with the below:
- A deeper understanding of the various business models demonstrated by digital therapeutic companies
- Up-to-date information on business models of varying successes in the current industry
- A clear understanding of if it’s possible to successfully a dual entity business or if companies truly have to “pick a side”
- A clear understanding of current routes to market and their intricacies
- Your questions answered by industry leaders and your peers
Acacia Parks, Chief Scientist, Happify
Jenna Carl, VP of Clinical Development & Medical Affairs, Big Health
Derek Richards, Chief Science Officer, SilverCloud Health
Anil Jina, Chief Medical Officer, Akili Interactive
- How do digital therapeutic clinical trials differ from traditional drug trials?
- An introduction of comparison groups and digital trial design
Led by leaders in the industry all with in-depth experience of DTx clinical trials, this panel will dive into clinical trial considerations when designing trials for digital therapeutics
- What are the requirements when designing digital therapeutic clinical trials?
- What does the FDA require from clinical trials for them to be acceptable?
- What does a SHAM/placebo look like in the DTx clinical trial?
- Should DTx companies and the FDA be working together to produce the right SHAM for each trial?
This is your chance to finalize your notes and prepare questions for the workshop leaders and your peers for after the break!
Splitting into smaller groups, each group will discuss their own views on digital therapeutic clinical trials and work on how best to move forward in this space.
- What are the current issues we face when designing clinical trials for digital therapeutics?
- What considerations should you have in mind when designing SHAM trials?
- What are the current guidelines for DTx clinical trials outlined by the FDA?
- How can we work with governing bodies to ensure DTx clinical trials are both suitable and feasible?
- What does a suitable and usable SHAM trial look like?
Representatives from each group will share their main points from their discussion with the whole workshop.
Workshop leaders and members from all groups will facilitate the discussion with their own thoughts and questions in this collaborative session.
Summary thoughts will be shared by workshop leaders and all participators will leave with the below:
- A clear understanding of the clinical trial landscape for digital therapeutics
- A deeper understanding of how best to build a SHAM/placebo for a DTx clinical trial
- An understanding of current FDA clinical trial guidelines in the space
- A greater understanding of important considerations to keep in mind when designing a DTx clinical trial
- Your questions answered by industry-leading experts and your peers
DTx West 2020 agenda
Summit Agenda
- Day 1: February 18th
- Day 2: February 19th
Adam Kaufman, President & CEO, Canary Health
Moderated by Brent Vaughan, Chief Executive Officer, Cognoa
Sean Duffy, Co-Founder & CEO, Omada Health
Alex Waldron, Chief Strategy Officer, Pear Therapeutics
Attendees are welcome to jump between tracks as they choose
Defining Evidence Standards for Digital Therapeutics
Chair: Acacia Parks, Chief Scientist, Happify
Acacia Parks, Chief Scientist, Happify
Veena Rao, Senior Director, Search & Evaluation, Device Delivery, Connected Systems & Digital Health, Eli Lilly
Mark Bini, VP, New Solutions, Express Scripts
Building the Value Proposition for Digital Therapeutics
Chair: Adam Kaufman, President & CEO, Canary Health
Antoun Nabhan, VP, Corporate Development, Pear Therapeutics
Jeff Abraham, VP of Market Access & Trade, Akili Interactive
Jennifer LaGuardia, Senior Director of Behaviour Science, Omada Health
Andy Molnar, Senior Director, Market Access, Cognoa
Clare Purvis, Director, Behaviour Sciences, Headspace
Derek Richards, Chief Science Officer, Silvercloud Health
Moderated by Sharief Taraman, Chief Medical Office, Cognoa
Debra Reisenthel, President & CEO, Palo Alto Health Sciences
Jenna Carl, VP of Clinical Development & Medical Affairs, Big Health
Jonas Duss, US Chief Executive Officer, Kaia Health
Chris Wasden, Head of Pharma, Happify Health
Mikael Eliasson, Global Head of Innovation, Neuroscience Product Development, Genentech
Chris Hogg, Chief Commercial Officer, Propeller Health
Ricardo Dos Santos, Entrepeneur in Residence, ResMed
Moderated by Ed Cox, CEO, Dthera Sciences
Pierre Leurent, Founder and CEO, Voluntis
Eddie Martucci, Founder & CEO, Akili Interactive
Megan Coder, Executive Director, Digital Therapeutics Alliance
Adam Kaufman, President & CEO, Canary Health
Antoun Nabhan, VP, Corporate Development, Pear Therapeutics
Elli Kaplan, Co-Founder & CEO, Neurotrack
Chris Hogg, CCO, Propeller Health
Anand Iyer, Chief Strategy Officer, Welldoc
Liz Rockett, Director, Kaiser Permanente Ventures
Vas Bailey, Partner, Artis Ventures
David Stevenson, Managing Director, Merck Global Health Innovation Fund
Siva Nadarajah, Co-Founder & President, JOGO Health
Kenichiro Nishii, Lead, Regulatory Affairs and Business Development, CureApp
Hakim Yadi, Co-Founder & CEO, Closed Loop Medicine
Trina Histon, Senior Principal Consultant, Prevention, Wellness and Digital Health, Kaiser Permanente
Shaundra Eichstrat, MD, Dermatology Resident, Tufts Medical Centre
Ben Rosner, Assistant Producer, UCSF
Pablo Panteoloni, VP & General Manager of Health, Headspace
Antoun Nabhan, VP, Corporate Development, Pear Therapeutics
DTx West Venue - The Marriott, San Mateo
We strive to provide inspirational venues that can provide the space needed for an open and widely networked event.
The 2020 summit is back at the Marriott San Mateo, a contemporary hotel just 10 minutes from SFO airport. For 2020 space is bigger and better.
Blending the look and feel of a first class resort with comfort and state of the art conference amenities this venue is the perfect place for learning, networking and relaxing.
Bedrooms can be booked directly with the hotel. We anticipate high demand and recommend that you book early to secure the best possible rate. The Marriott does not offer an exclusive rate for DTx attendees. We have included, in the welcome pack, details of alternative hotels close to the DTx venue.
Partner with us
PARTNERSHIPS
The DTx summits are the premier events for senior executives from DTx companies, Pharma, Investors, HCPs and Payers.
DTx West 2020 is the seventh summit in the DTx series. We are expecting 300 people at the summit in San Mateo, which is what our attendees and partnersa tell us is the optimum size
We believe that getting the right mix of partners is critical for a successful summit for you and our attendees. The DTx summit provides a rare opportunity to showcase your business to a world-class audience.
You will be impressed with our service and truthfulness. We will be honest with you throughout the process from deciding which option is right for you to delivery on-site.
Get in touch today to learn more and avoid missing out!
Register for the Event
Early Booking Price expires November 22nd.
For pricing and booking options please click the button to go to the registration page.